Nifekalant hydrochloride, a novel class III antiarrhythmic agent, suppressed postoperative recurrent ventricular tachycardia in a patient undergoing coronary artery bypass grafting and the Dor approach

Circ J. 2003 Aug;67(8):712-4. doi: 10.1253/circj.67.712.

Abstract

A patient with 3-vessel coronary artery disease and left ventricular aneurysm underwent coronary artery bypass grafting combined with the Dor approach. Five days later, ventricular tachycardia following short-coupled ventricular premature contractions suddenly occurred and was not responsive to class IB drugs (lidocaine and mexiletine), requiring frequent electrical cardioversion. After the administration of a novel class III drug, nifekalant hydrochloride, this electrical storm of ventricular tachycardia was completely suppressed together with the disappearance of ventricular premature contractions. Nifekalant hydrochloride (MS-551), a pure K(+) channel blocker, might be effective for postoperative recurrent ventricular tachyarrhythmias that are refractory to other antiarrhythmic agents.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Arrhythmia Agents / classification
  • Anti-Arrhythmia Agents / therapeutic use*
  • Coronary Artery Bypass / adverse effects*
  • Drug Resistance
  • Electric Countershock
  • Electrocardiography
  • Humans
  • Lidocaine / therapeutic use
  • Male
  • Mexiletine / therapeutic use
  • Potassium Channel Blockers / therapeutic use*
  • Pyrimidinones / therapeutic use*
  • Tachycardia, Ventricular / diagnosis
  • Tachycardia, Ventricular / drug therapy*
  • Tachycardia, Ventricular / etiology*
  • Tachycardia, Ventricular / therapy

Substances

  • Anti-Arrhythmia Agents
  • Potassium Channel Blockers
  • Pyrimidinones
  • Mexiletine
  • nifekalant
  • Lidocaine